Table 3.
Summary of clinical trials with NGF on skin ulcers
| Disease | Study type | NGF type and dosage | Delivery route | Outcome | Side effects | References |
|---|---|---|---|---|---|---|
| Diabetic foot ulcers |
Three patients case report. |
Mouse NGF. 25 μg/day for 4 weeks. |
Topical (skin). |
Progressive restoration of nerve function and relapse of ulcers within 5–14 weeks since the beginning of treatment. |
Not reported. |
[154] |
| Vasculitic ulcers |
Eight patients case report. |
Mouse NGF. 50 μg/day for 4 weeks. |
Topical (skin). |
Ulcers healing within 8 weeks in rheumatoid arthritis patients (n=4). Failure of ulcers healing in systemic sclerosis patients (n=4). |
Not reported. |
[155] |
| Pressure ulcers |
Single patient case study. |
Mouse NGF. |
Topical (skin). |
Ulcer size reduced by 1/3 after 15 days treatment. |
Not reported. |
[156] |
| |
Randomized, double-blind, placebo-controlled trial. |
Mouse NGF. |
Topical (skin). |
Reduction of ulcer area in the 6 weeks follow-up. |
Not reported. |
[157] |
| Lower limb crush syndrome | Single patient case study. | Mouse NGF. 10 μg every eight hours for seven days. | Subcutaneous. | Reduction of overall ischemic area. Reduction of the area undergoing calcaneal escharotomy. | Not reported. | [158] |